Granular cell myoblastoma: an immunoperoxidase study using a variety of antisera to human carcinoembryonic antigen.

Immunoperoxidase staining using five antisera to human carcinoembryonic antigen (CEA), including a mouse monoclonal antibody, was performed to investigate the expression of CEA reactivity in ten cases of granular cell myoblastoma. The granular cells were negative with four of the antisera although control sections of CEA producing colon carcinoma were positive. The single positive antiserum gave intense granular cytoplasmic staining of all tumour cells in the ten specimens studied. This reactivity was abolished after absorption of the antiserum with a perchloric acid extract of human lung to remove cross-reacting antibodies against non-specific cross-reacting antigen (NCA); a procedure which did not affect the staining of colon carcinoma specimens. The results indicate that the granular cells do not contain CEA but express a related antigen and that care in the choice of primary antiserum is important if the immunocytochemical detection of this antigen is to be used as a diagnostic aid.
AuthorsJ B Matthews, G I Mason
JournalHistopathology (Histopathology) Vol. 7 Issue 1 Pg. 77-82 (Jan 1983) ISSN: 0309-0167 [Print] ENGLAND
PMID6301969 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Carcinoembryonic Antigen
  • Immune Sera
  • Animals
  • Antibodies, Monoclonal (immunology)
  • Carcinoembryonic Antigen (analysis)
  • Colonic Neoplasms (immunology)
  • Humans
  • Immune Sera (immunology)
  • Immunoenzyme Techniques
  • Mice
  • Mouth Neoplasms (immunology)
  • Neoplasms, Muscle Tissue (immunology)
  • Palatal Neoplasms (immunology)
  • Rabbits
  • Sheep
  • Tongue Neoplasms (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: